Swiss National Bank boosted its position in Depomed Inc. (NASDAQ:DEPO) by 0.9% during the second quarter, Holdings Channel reports. The fund owned 103,000 shares of the specialty pharmaceutical company’s stock after buying an additional 900 shares during the period. Swiss National Bank owned about 0.17% of Depomed worth $2,021,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of DEPO. Envestnet Asset Management Inc. raised its position in shares of Depomed by 49.9% in the first quarter. Envestnet Asset Management Inc. now owns 23,457 shares of the specialty pharmaceutical company’s stock worth $327,000 after buying an additional 7,810 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Depomed by 29.3% in the first quarter. Legal & General Group Plc now owns 15,110 shares of the specialty pharmaceutical company’s stock valued at $211,000 after buying an additional 3,423 shares during the period. Consonance Capital Management LP bought a new stake in shares of Depomed during the first quarter valued at about $38,396,000. Geode Capital Management LLC increased its stake in shares of Depomed by 6.7% in the first quarter. Geode Capital Management LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock valued at $5,774,000 after buying an additional 26,160 shares during the period. Finally, UBS Asset Management Americas Inc. increased its stake in shares of Depomed by 17.7% in the first quarter. UBS Asset Management Americas Inc. now owns 31,896 shares of the specialty pharmaceutical company’s stock valued at $444,000 after buying an additional 4,800 shares during the period.

Depomed Inc. (NASDAQ:DEPO) traded up 0.12% on Tuesday, hitting $24.22. The stock had a trading volume of 1,206,567 shares. The firm has a 50-day moving average of $21.03 and a 200 day moving average of $18.52. The company’s market capitalization is $1.49 billion. Depomed Inc. has a 52 week low of $12.25 and a 52 week high of $27.26.

Depomed (NASDAQ:DEPO) last released its earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.01. The company earned $116.70 million during the quarter, compared to analysts’ expectations of $118.20 million. Depomed had a positive return on equity of 3.71% and a negative net margin of 16.89%. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.27 EPS. On average, analysts predict that Depomed Inc. will post $1.21 earnings per share for the current year.

Several equities research analysts recently issued reports on the company. Janney Montgomery Scott reiterated a “buy” rating and set a $28.00 price target on shares of Depomed in a report on Wednesday, September 14th. Mizuho upped their price target on Depomed from $23.00 to $27.00 and gave the stock a “buy” rating in a report on Friday. Cantor Fitzgerald reiterated a “buy” rating on shares of Depomed in a report on Thursday, August 11th. Piper Jaffray Cos. reiterated a “neutral” rating and set a $19.00 price target (up previously from $18.00) on shares of Depomed in a report on Thursday, August 4th. Finally, JMP Securities decreased their price target on Depomed from $28.00 to $22.00 and set a “market outperform” rating for the company in a report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. Depomed presently has a consensus rating of “Buy” and a consensus price target of $22.98.

In other Depomed news, CFO August J. Moretti sold 5,000 shares of Depomed stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $21.40, for a total transaction of $107,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Thadd M. Vargas sold 26,290 shares of Depomed stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $20.92, for a total value of $549,986.80. Following the transaction, the vice president now owns 84,336 shares of the company’s stock, valued at approximately $1,764,309.12. The disclosure for this sale can be found here. Company insiders own 5.12% of the company’s stock.

About Depomed

5 Day Chart for NASDAQ:DEPO

Want to see what other hedge funds are holding DEPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Depomed Inc. (NASDAQ:DEPO).

Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.